Matthias Cavassini

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


520 publications

Sous presse | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | ...
Sous presse
 
Deciphering factors linked with reduced SARS-CoV-2 susceptibility in the Swiss HIV Cohort Study.
Abela I.A., Hauser A., Schwarzmüller M., Pasin C., Kusejko K., Epp S., Cavassini M., Battegay M., Rauch A., Calmy A. et al. The Journal of infectious diseases. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F53FC91CC440]
 
Circulating HBV RNA and hepatitis B core-related antigen trajectories in persons with HIV/HBV coinfection and HBsAg loss on tenofovir therapy.
Begré L., Boyd A., Plissonnier M.L., Testoni B., Salazar-Vizcaya L., Suter-Riniker F., Scholtès C., Béguelin C., Rockstroh J.K., Günthard H.F. et al. The Journal of infectious diseases. Peer-reviewed.
[DOI][Pmid][serval:BIB_7C1C4A6067C9]
 
Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide (TAF) in people with HIV.
Damas J., Munting A., Fellay J., Haerry D., Marzolini C., Tarr P.E., Steffen A., Braun D.L., Stoeckle M., Bernasconi E. et al. Clinical infectious diseases. Peer-reviewed.
[DOI][Pmid][serval:BIB_A22E1C92231B]
 
Cardiovascular Disease Risk Factor Control in People With and Without Human Immunodeficiency Virus.
Silverberg M.J., Levine T.M., Lea A.N., Williams A.E., Alexeeff S.E., Bryant K., Cavassini M., Flamm J.A., Hare C.B., Ingle S.M. et al. Clinical infectious diseases. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_30B7DB913B8C]
 
Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV.
Thoueille P., Saldanha S.A., Schaller F., Choong E., Veuve F., Munting A., Cavassini M., Braun D., Günthard H.F., Duran Ramirez J.J. et al. Clinical pharmacology and therapeutics. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A008171B295E]
 
Time Trends in Causes of Death in People with HIV: Insights from the Swiss HIV Cohort Study.
Weber MSR, Duran Ramirez J.J., Hentzien M., Cavassini M., Bernasconi E., Hofmann E., Furrer H., Kovari H., Stöckle M., Schmid P. et al. Clinical infectious diseases. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5CD744C2EE1B]
 
Genetic diversity from proviral DNA as a proxy for time since HIV-1 infection.
Zeeb M., Frischknecht P., Huber M., Schenkel C.D., Neumann K., Leeman C., Notter J., Rauch A., Stöckle M., Cavassini M. et al. The Journal of infectious diseases. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BB49B254C104]
2024
 
Characterization and Determinants of Long-Term Immune Recovery Under Suppressive Antiretroviral Therapy.
Turk T., Labarile M., Braun D.L., Rauch A., Stöckle M., Cavassini M., Hoffmann M., Calmy A., Bernasconi E., Notter J. et al., 2024/05/01. Journal of acquired immune deficiency syndromes, 96 (1) pp. 68-76. Peer-reviewed.
[DOI][Pmid][serval:BIB_AF6A60365EE4]
 
Prophylaxie pré-exposition au VIH : les médecins ne sont pas préparés [HIV pre-exposure prophylaxis: physicians are not prepared]
Badoux M., Damas J., Cobos Manuel I., Cavassini M., Munting A., 2024/04/10. Revue medicale suisse, 20 (869) pp. 748-755. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_EEDC8D0D824F]
The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers.
Gasca-Capote C., Lian X., Gao C., Roseto I.C., Jiménez-León M.R., Gladkov G., Camacho-Sojo M.I., Pérez-Gómez A., Gallego I., Lopez-Cortes L.E. et al., 2024/02/20. The Journal of clinical investigation, 134 (8). Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B3A795F338D3]
Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures.
Thoueille P., Cavassini M., Guidi M., Buclin T., Girardin F.R., Decosterd L.A., Marzolini C., 2024/02. Open forum infectious diseases, 11 (2) pp. ofae023. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E70DD8E56C37]
Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy.
Begré L., Boyd A., Salazar-Vizcaya L., Suter-Riniker F., Béguelin C., Rockstroh J.K., Günthard H.F., Calmy A., Cavassini M., Stöckle M. et al., 2024/02. HIV medicine, 25 (2) pp. 291-298. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_575061651828]
Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data.
Berton M., Bettonte S., Stader F., Decosterd L., Tarr P.E., Livio F., Cavassini M., Braun D.L., Kusejko K., Hachfeld A. et al., 2024/01/25. Clinical infectious diseases, 78 (1) pp. 98-110. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CE2036172D19]
 
Estimation of Improvements in Mortality in Spectrum Among Adults With HIV Receiving Antiretroviral Therapy in High-Income Countries.
Trickey A., Glaubius R., Pantazis N., Zangerle R., Wittkop L., Vehreschild J., Grabar S., Cavassini M., Teira R., d'Arminio Monforte A. et al., 2024/01/01. Journal of acquired immune deficiency syndromes, 95 (1S) pp. e89-e96. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4E741D433714]
Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study.
Baumann L., Braun D.L., Cavassini M., Stoeckle M., Bernasconi E., Schmid P., Calmy A., Haerry D., Béguelin C., Fux C.A. et al., 2024/01. Liver international, 44 (1) pp. 169-179. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_67D0635AAB87]
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.
Thoueille P., Saldanha S.A., Schaller F., Choong E., Munting A., Cavassini M., Braun D., Günthard H.F., Kusejko K., Surial B. et al., 2024/01. The Lancet regional health. Europe, 36 p. 100793. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_EE4919775F0F]
2023
Understanding the Decline of Incident, Active Tuberculosis in People With Human Immunodeficiency Virus in Switzerland.
Zeeb M., Tepekule B., Kusejko K., Reiber C., Kälin M., Bartl L., Notter J., Furrer H., Hoffmann M., Hirsch H.H. et al., 2023/11/11. Clinical infectious diseases, 77 (9) pp. 1303-1311. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6C8758C4EEB4]
 
Remise des autotests VIH en pharmacie d’officine. État des lieux et recommandations de pratique pour une collaboration interprofessionnelle [HIV self-tests in community pharmacies Inventory and practice recommendations for interprofessional collaborations]
Rousseau M., Solh Dost S., Santos B., Gauthier R., Cavassini M., Calmy A., Schneider M., 2023/10/25. Revue medicale suisse, 19 (847) pp. 2017-2020. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_4CB57217B4BE]
Lymph node dendritic cells harbor inducible replication-competent HIV despite years of suppressive ART.
Banga R., Procopio F.A., Lana E., Gladkov G.T., Roseto I., Parsons E.M., Lian X., Armani-Tourret M., Bellefroid M., Gao C. et al., 2023/10/11. Cell host & microbe, 31 (10) pp. 1714-1731.e9. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9F739E97B9B6]
 
Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018.
Jaha B., Schenkel C.D., Jörimann L., Huber M., Zaheri M., Neumann K., Leemann C., Calmy A., Cavassini M., Kouyos R.D. et al., 2023/09/05. The Journal of antimicrobial chemotherapy, 78 (9) pp. 2323-2334. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B803006D685B]
Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor-containing regimen.
Marzolini C., Cavassini M., Braun D.L., Hachfeld A., Bernasconi E., Calmy A., Schmid P., Battegay M., Elzi L., Swiss HIV Cohort Study, 2023/09. British journal of clinical pharmacology, 89 (9) pp. 2739-2746. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0B5571DA9173]
 
Sexual Behaviour and STI Incidence in Sexually Active MSM Living With HIV in Times of COVID-19.
Mugglin C., Hamusonde K., Salazar-Vizcaya L., Kusejko K., Nicca D., Haerry D., Braun D.L., Stoeckle M., Kouyos R., Calmy A. et al., 2023/08. Open forum infectious diseases, 10 (8) pp. ofad399. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E0E350C73D08]
Cerebrospinal Fluid HIV-1 Escape in Patients With Neurocognitive Symptoms: Pooled Data From a Neuro-HIV Platform and the NAMACO Study.
Filippidis P., Damas J., Viala B., Assal F., Nawej Tshikung O., Tarr P., Derfuss T., Oberholzer M., Jelcic I., Hundsberger T. et al., 2023/07/01. Journal of acquired immune deficiency syndromes, 93 (3) pp. 219-228. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_369AC239E3C3]
Leukocyte Count and Coronary Artery Disease Events in People With Human Immunodeficiency Virus: A Longitudinal Study.
Avery E.F., Kleynhans J.N., Ledergerber B., Schoepf I.C., Thorball C.W., Kootstra N.A., Reiss P., Ryom L., Braun D.L., Thurnheer M.C. et al., 2023/06/08. Clinical infectious diseases, 76 (11) pp. 1969-1979. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E1546C7A7084]
One for all, all for one: neuro-HIV multidisciplinary platform for the assessment and management of neurocognitive complaints in people living with HIV.
Damas J., Darling KEA, Bidlingmeyer P., Nadin-Debluë I., Bieler M., Vollino L., Sokolov A.A., Berney A., Maccaferri G., Filippidis P. et al., 2023/06. HIV medicine, 24 (6) pp. 738-748. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EC28428CED42]
Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration.
Thoueille P., Alves Saldanha S., Desfontaine V., Kusejko K., Courlet P., Andre P., Cavassini M., Decosterd L.A., Buclin T., Guidi M. et al., 2023/06/01. The Journal of antimicrobial chemotherapy, 78 (6) pp. 1433-1443. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_449BF24E5A20]
 
Utilité du TDM des anti-rétroviraux: passé, présent, futur
Choong Eva, Thoueille Paul, Cavassini M., Decosterd Laurent, 2023/05/04. dans Association pour la ormation en Analyses de Biologie Spécialisée (AFABS) - Journée de formation du 4 mai 2023 - Lausanne . Peer-reviewed.
[serval:BIB_D453D7DC90C4]
 
Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic Suppression.
Castillo-Mancilla J.R., Morrow M., Hunt P.W., Schnittman S.R., Phillips A.N., Baker J.V., Haberer J.E., Janeiro M.J., Aragao F., Cohen C. et al., 2023/05. Open forum infectious diseases, 10 (5) pp. ofad230. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BE4B4FF3A440]
Comparison of five different risk scores to predict incident type 2 diabetes in the Swiss HIV cohort study.
Blondet F., Kraege V., Cavassini M., Damas Fernandez J., Vollenweider P., Wandeler G., Hoffman M., Calmy A., Stoeckle M., Bernasconi E. et al., 2023/05/01. AIDS, 37 (6) pp. 935-939. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6907E8AE8380]
 
Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years.
Schoepf I.C., Esteban-Cantos A., Thorball C.W., Rodés B., Reiss P., Rodríguez-Centeno J., Riebensahm C., Braun D.L., Marzolini C., Seneghini M. et al., 2023/05. The lancet. Healthy longevity, 4 (5) pp. e211-e218. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_689682CD15B9]
 
Troubles cognitifs chez les personnes vivant avec le VIH. L’importance d’une prise en charge multidisciplinaire [Multidisciplinary assessment and management of neurocognitive complaints in people living with HIV]
Damas J., Berney A., Bieler-Aeschlimann M., Cavassini M., Du Pasquier R., 2023/04/26. Revue medicale suisse, 19 (824) pp. 797-799. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A5FA8E8B5103]
 
Réponses innovantes pour faire face aux enjeux liés au VIH dans un hôpital universitaire en Suisse [Innovative responses to HIV-related issues in a university hospital in Switzerland]
Cobos Manuel I., Courvoisier C., Rhis M.F., Depallens R., Buvelot Corthesy C., Muggli E., Cavassini M., Jackson-Perry D., 2023/04/12. Revue medicale suisse, 19 (822) pp. 732-735. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_710279EBD57E]
 
Échinococcose alvéolaire : prise en charge en 2023 [2023 update on alveolar echinococcosis]
Gauthiez E., Uldry E., Coste A.T., Prior J., Cavassini M., Munting A., 2023/04/12. Revue medicale suisse, 19 (822) pp. 708-712. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_3120FE82293D]
 
Rectal shedding of monkeypox virus in a patient coinfected with Chlamydia trachomatis and Neisseria gonorrhoeae: a case report.
Desgranges F., Glampedakis E., Christinet V., Encarnação S., Fernandes C., Greub G., Opota O., Cavassini M., 2023/03/06. Journal of medical case reports, 17 (1) p. 94. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4F21C7D1F691]
 
Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1.
Balakrishna S., Loosli T., Zaheri M., Frischknecht P., Huber M., Kusejko K., Yerly S., Leuzinger K., Perreau M., Ramette A. et al., 2023/03/02. The Journal of antimicrobial chemotherapy, 78 (3) pp. 656-664. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_213147216CE3]
 
Quantifying and Predicting Ongoing Human Immunodeficiency Virus Type 1 Transmission Dynamics in Switzerland Using a Distance-Based Clustering Approach.
Labarile M., Loosli T., Zeeb M., Kusejko K., Huber M., Hirsch H.H., Perreau M., Ramette A., Yerly S., Cavassini M. et al., 2023/02/14. The Journal of infectious diseases, 227 (4) pp. 554-564. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AAE8A3C815DF]
Female Genital Mutilation/Cutting in the Swiss HIV Cohort Study: A Cross-Sectional Study.
Mauri F., Cottler-Casanova S., Cavassini M., Stoeckle M., Wandeler G., Schmid P., Braun D.L., Scherrer A., Bernasconi E., Calmy A. et al., 2023/02. Journal of immigrant and minority health, 25 (1) pp. 136-141. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B5094BDB2252]
 
VIH : zoom sur les traitements injectables à longue durée d’action [News in HIV infection, long-acting injectable treatments]
Nawej Tshikung O., Segeral O., Cavassini M., Calmy A., 2023/02/01. Revue medicale suisse, 19 (812) pp. 243-249. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_F1169B5D735F]
2022
 
Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens.
Bannister W.P., Mast T.C., de Wit S., Gerstoft J., Wiese L., Milinkovic A., Hadziosmanovic V., Clarke A., Rasmussen L.D., Lacombe K. et al., 2022/12/01. AIDS, 36 (15) pp. 2107-2119. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4C81A57F2CA6]
Risk Factors and Incidence of Sexually Transmitted Infections in the Swiss HIV Cohort Study.
Bosetti D., Mugglin C., Calmy A., Cavassini M., Stöckle M., Braun D., Notter J., Haerry D., Hampel B., Kovari H. et al., 2022/12. Open forum infectious diseases, 9 (12) pp. ofac592. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_52A653706C5D]
Women with Cervical High-Risk Human Papillomavirus: Be Aware of Your Anus! The ANGY Cross-Sectional Clinical Study.
Jacot-Guillarmod M., Balaya V., Mathis J., Hübner M., Grass F., Cavassini M., Sempoux C., Mathevet P., Pache B., 2022/10/18. Cancers, 14 (20) p. 5096. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_06656493BDD9]
Low Risk of Failing Direct-Acting Antivirals in People With Human Immunodeficiency Virus/Hepatitis C Virus From Sub-Saharan Africa or Southeastern Asia: A European Cross-Sectional Study.
Isfordink C., Boyd A., Mocroft A., Kusejko K., Smit C., de Wit S., Mahungu T., Falconer K., Wandeler G., Cavassini M. et al., 2022/10. Open forum infectious diseases, 9 (10) pp. ofac508. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_248BB720D736]
 
A Systematic Molecular Epidemiology Screen Reveals Numerous Human Immunodeficiency Virus (HIV) Type 1 Superinfections in the Swiss HIV Cohort Study.
Chaudron S.E., Leemann C., Kusejko K., Nguyen H., Tschumi N., Marzel A., Huber M., Böni J., Perreau M., Klimkait T. et al., 2022/09/28. The Journal of infectious diseases, 226 (7) pp. 1256-1266. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F747BBEF0F8F]
 
Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus.
Jakeman B., Scherrer A.U., Darling KEA, Damas J., Bieler-Aeschlimann M., Hasse B., Schlosser L., Hachfeld A., Gutbrod K., Tarr P.E. et al., 2022/09. Open forum infectious diseases, 9 (9) pp. ofac457. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_06A5B894B7FF]
A Phylogeny-aware GWAS Framework to Correct for Heritable Pathogen Effects on Infectious Disease Traits.
Nadeau S., Thorball C.W., Kouyos R., Günthard H.F., Böni J., Yerly S., Perreau M., Klimkait T., Rauch A., Hirsch H.H. et al., 2022/08/03. Molecular biology and evolution, 39 (8) pp. msac163. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C0A2EB45D9AE]
Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 Epidemics.
Kusejko K., Tschumi N., Chaudron S.E., Nguyen H., Battegay M., Bernasconi E., Böni J., Huber M., Calmy A., Cavassini M. et al., 2022/08/01. Journal of acquired immune deficiency syndromes, 90 (4) pp. e4-e12. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6FD8C532081B]
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.
Thoueille P., Alves Saldanha S., Schaller F., Munting A., Cavassini M., Braun D., Günthard H.F., Kusejko K., Surial B., Furrer H. et al., 2022/07/29. Pharmaceutics, 14 (8) p. 1588. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EA4A25E4F31E]
 
Author Correction: Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV.
Bick A.G., Popadin K., Thorball C.W., Uddin M.M., Zanni M.V., Yu B., Cavassini M., Rauch A., Tarr P., Schmid P. et al., 2022/07/08. Scientific reports, 12 (1) p. 11638. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3C87FA69CB82]
 
Correction to: Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group.
Nguyen H., Hampel B., Nuñez D.G., Battegay M., Hachfeld A., Bernasconi E., Calmy A., Cavassini M., Vernazza P., Fellay J. et al., 2022/07/06. Clinical infectious diseases, 74 (12) p. 2266. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7D8CAA9F6BAD]
Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells.
Munoz O., Banga R., Schelling R., Procopio F.A., Mastrangelo A., Nortier P., Ohmiti K., Daraspe J., Cavassini M., Fenwick C. et al., 2022/07. PLoS pathogens, 18 (7) pp. e1010673. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BEB839579791]
 
The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study.
Mocroft A., Miro J.M., Wandeler G., Llibre J.M., Boyd A., van Bremen K., Beniowski M., Mikhalik J., Cavassini M., Maltez F. et al., 2022/07. HIV medicine, 23 (6) pp. 585-598. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7542D67528C1]
Changes in mental and sexual health among MSM using HIV pre-exposure prophylaxis during the SARS-CoV-2 pandemic: longitudinal analysis of the SwissPrEPared cohort study.
Winter B.L., Hovaguimian F., Kouyos R.D., Schmidt A.J., Bernasconi E., Braun D.L., Calmy A., Notter J., Stoeckle M., Surial B. et al., 2022/06/20. Swiss medical weekly, 152 pp. w30192. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_80B3E54B7ADE]
 
Impact of Latent Tuberculosis on Diabetes.
Tepekule B., Kusejko K., Zeeb M., Tarr P.E., Calmy A., Battegay M., Furrer H., Cavassini M., Bernasconi E., Notter J. et al., 2022/06/15. The Journal of infectious diseases, 225 (12) pp. 2229-2234. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_878BF720EE16]
Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study.
Trickey A., Zhang L., Gill M.J., Bonnet F., Burkholder G., Castagna A., Cavassini M., Cichon P., Crane H., Domingo P. et al., 2022/06. The lancet. HIV, 9 (6) pp. e404-e413. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E8576CCDA5CB]
 
Decreasing Incidence and Determinants of Bacterial Pneumonia in People With HIV: The Swiss HIV Cohort Study.
Balakrishna S., Wolfensberger A., Kachalov V., Roth J.A., Kusejko K., Scherrer A.U., Furrer H., Hauser C., Calmy A., Cavassini M. et al., 2022/05/04. The Journal of infectious diseases, 225 (9) pp. 1592-1600. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_92754B1AC422]
 
Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years.
Schoepf I.C., Thorball C.W., Ledergerber B., Kootstra N.A., Reiss P., Raffenberg M., Engel T., Braun D.L., Hasse B., Thurnheer C. et al., 2022/05/04. The Journal of infectious diseases, 225 (9) pp. 1581-1591. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_39DB29D8297F]
 
Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group.
Nguyen H., Hampel B., Garcia Nuñez D., Battegay M., Hachfeld A., Bernasconi E., Calmy A., Cavassini M., Vernazza P., Fellay J. et al., 2022/04/28. Clinical infectious diseases, 74 (8) pp. 1468-1475. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_966C936A2B27]
High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus.
Herderschee J., Heinonen T., Fenwick C., Schrijver I.T., Ohmiti K., Moradpour D., Cavassini M., Pantaleo G., Roger T., Calandra T. et al., 2022/04. Clinical microbiology and infection, 28 (4) pp. 611.e1-611.e7. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_300AF1BADC64]
 
Cardiovascular risk assessment in people living with HIV compared to the general population.
Delabays B., Cavassini M., Damas J., Beuret H., Calmy A., Hasse B., Bucher H.C., Frischknecht M., Müller O., Méan M. et al., 2022/03/30. European journal of preventive cardiology, 29 (4) pp. 689-699. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9625723A86C9]
EBV-positive large B-cell lymphoma with an unusual intravascular presentation and associated haemophagocytic syndrome in an HIV-positive patient: report of a case expanding the spectrum of EBV-positive immunodeficiency-associated lymphoproliferative disorders.
Veloza L., Tsai C.Y., Bisig B., Pantet O., Alberio L., Sempoux C., Cavassini M., de Leval L., 2022/03. Virchows Archiv, 480 (3) pp. 699-705. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_24812BA3BF72]
HIV testing in termination of pregnancy and colposcopy services: a scoping review.
Filippidis P., Francini K., Jacot-Guillarmod M., Mathevet P., Lhopitallier L., Cavassini M., Darling KEA, 2022/03. Sexually transmitted infections, 98 (2) pp. 143-149. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FF4DA9AE3D72]
 
Cohort Profile Update: The Swiss HIV Cohort Study (SHCS).
Scherrer A.U., Traytel A., Braun D.L., Calmy A., Battegay M., Cavassini M., Furrer H., Schmid P., Bernasconi E., Stoeckle M. et al., 2022/02/18. International journal of epidemiology, 51 (1) pp. 33-34j. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CAE07421BB63]
 
Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study.
Jakeman B., Scherrer A., Battegay M., Gunthard H.F., Hachfeld A., Calmy A., Schmid P., Bernasconi E., Cavassini M., Marzolini C., 2022/02/02. The Journal of antimicrobial chemotherapy, 77 (2) pp. 492-499. Peer-reviewed.
[DOI][Pmid][serval:BIB_9473F480CF4D]
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection.
Thoueille P., Choong E., Cavassini M., Buclin T., Decosterd L.A., 2022/02/02. The Journal of antimicrobial chemotherapy, 77 (2) pp. 290-302. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C31B6241296B]
 
Increasing Frequency and Transmission of HIV-1 Non-B Subtypes Among Men Who Have Sex With Men in the Swiss HIV Cohort Study.
Duran Ramirez J.J., Ballouz T., Nguyen H., Kusejko K., Chaudron S.E., Huber M., Hirsch H.H., Perreau M., Ramette A., Yerly S. et al., 2022/01/18. The Journal of infectious diseases, 225 (2) pp. 306-316. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A7E78283DB80]
Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV.
Bick A.G., Popadin K., Thorball C.W., Uddin M.M., Zanni M.V., Yu B., Cavassini M., Rauch A., Tarr P., Schmid P. et al., 2022/01/12. Scientific reports, 12 (1) p. 577. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_482297EB27F3]
 
Long-term trends of alanine aminotransferase levels among persons living with human immunodeficiency virus/hepatitis B virus with and without hepatitis delta coinfection.
Begré L., Béguelin C., Boyd A., Peters L., Rockstroh J., Günthard H.F., Bernasconi E., Cavassini M., Lacombe K., Mocroft A. et al., 2022. Frontiers in medicine, 9 p. 988356. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B47685CB8341]
Medication Adherence Evaluated Through Electronic Monitors During the 2020 COVID-19 Pandemic Lockdown in Switzerland: A Longitudinal Analysis.
Bandiera C., Pasquier J., Locatelli I., Niquille A., Wuerzner G., Dotta-Celio J., Hachfeld A., Wandeler G., Wagner A.D., Csajka C. et al., 2022. Patient preference and adherence, 16 pp. 2313-2320. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_813F43A545D0]
Prevalence of anal dysplasia and HPV genotypes in gynecology patients: The ANGY cross-sectional prospective clinical study protocol.
Pache B., Balaya V., Mathis J., Hübner M., Sahli R., Cavassini M., Sempoux C., Mathevet P., Jacot-Guillarmod M., 2022. PloS one, 17 (10) pp. e0276438. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_74630FA51C0D]
The deficiency in Th2-like Tfh cells affects the maturation and quality of HIV-specific B cell response in viremic infection.
Noto A., Suffiotti M., Joo V., Mancarella A., Procopio F.A., Cavet G., Leung Y., Corpataux J.M., Cavassini M., Riva A. et al., 2022. Frontiers in immunology, 13 p. 960120. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3A9147719CB5]
 
Travailleuses du sexe et accès aux soins
Gloor Élodie, Meystre-Agustoni Giovanna, Ansermet Pagot Anne, Vaucher Paul, Durieux-Paillard Sophie, Bodenmann Patrick, Cavassini Matthias, 2022. pp. 317-326 dans Bodenmann Patrick, Jackson Yves, Vu Francis, Wolff Hans (eds.) Vulnérabilités, diversités et équité en santé chap. 2.5, RMS éditions / Médecine et Hygiène.
[serval:BIB_6E821499F674]
2021
 
A 31-Year-Old Patient Living With Human Immunodeficiency Virus With Thyroiditis and Multiple Intrathoracic Lesions.
Filippidis P., Barras J.L., Cavassini M., Kritikos A., 2021/12/16. Clinical infectious diseases, 73 (12) pp. 2361-2364. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CB38714032AE]
Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIV.
Damas J., Ledergerber B., Nadin I., Tarr P.E., Stoeckle M., Kunze U., Hauser C., Gutbrod K., Calmy A., Assal F. et al., 2021/12/01. AIDS, 35 (15) pp. 2469-2480. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9183F35782B2]
 
Coronary Artery Disease-Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study.
Schoepf I.C., Thorball C.W., Ledergerber B., Engel T., Raffenberg M., Kootstra N.A., Reiss P., Hasse B., Marzolini C., Thurnheer C. et al., 2021/11/02. Clinical infectious diseases, 73 (9) pp. 1597-1604. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_782F7251FD8F]
 
Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial.
Courlet P., Barbieux C., Sculier D., Wandeler G., Stoeckle M., Bernasconi E., Braun D., Vernazza P., Cavassini M., Marinosci A. et al., 2021/11. British journal of clinical pharmacology, 87 (11) pp. 4455-4460. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_87880AB3A5A2]
A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
Speich B., Chammartin F., Smith D., Stoeckle M.P., Amico P., Eichenberger A.L., Hasse B., Schuurmans M.M., Müller T., Tamm M. et al., 2021/10/21. Trials, 22 (1) p. 724. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B5A01BBEEB3D]
 
Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study.
Roth J.A., Radevski G., Marzolini C., Rauch A., Günthard H.F., Kouyos R.D., Fux C.A., Scherrer A.U., Calmy A., Cavassini M. et al., 2021/10/13. The Journal of infectious diseases, 224 (7) pp. 1198-1208. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_01426653908F]
 
Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment.
Pyngottu A., Scherrer A.U., Kouyos R., Huber M., Hirsch H., Perreau M., Yerly S., Calmy A., Cavassini M., Stöckle M. et al., 2021/10/05. Clinical infectious diseases, 73 (7) pp. e2134-e2141. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FCC193ED7F6C]
 
Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors.
Deutschmann E., Bucher H.C., Jaeckel S., Gibbons S., McAllister K., Scherrer A.U., Braun D.L., Cavassini M., Hachfeld A., Calmy A. et al., 2021/10/05. Clinical infectious diseases, 73 (7) pp. e2145-e2152. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D84973BFC460]
Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study.
Balakrishna S., Salazar-Vizcaya L., Schmidt A.J., Kachalov V., Kusejko K., Thurnheer M.C., Roth J.A., Nicca D., Cavassini M., Battegay M. et al., 2021/10. PLoS computational biology, 17 (10) pp. e1009529. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F8B56F9C05F3]
 
Seasonal trivalent inactivated influenza vaccine with topical imiquimod in immunocompromised patients: A randomized controlled trial.
Mombelli M., Hoschler K., Cavassini M., Pascual M., Manuel O., 2021/09. The Journal of infection, 83 (3) pp. 354-360. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8399DF169607]
 
Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
Kovari H., Surial B., Tarr P.E., Cavassini M., Calmy A., Schmid P., Bernasconi E., Rauch A., Wandeler G., Ledergerber B. et al., 2021/08. HIV medicine, 22 (7) pp. 623-628. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7C0015304E9E]
Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma.
Thorball C.W., Oudot-Mellakh T., Ehsan N., Hammer C., Santoni F.A., Niay J., Costagliola D., Goujard C., Meyer L., Wang S.S. et al., 2021/08/01. Haematologica, 106 (8) pp. 2233-2241. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B72746EA3CA7]
Forgiveness of Dolutegravir-Based Triple Therapy Compared With Older Antiretroviral Regimens: A Prospective Multicenter Cohort of Adherence Patterns and HIV-RNA Replication.
Parienti J.J., Fournier A.L., Cotte L., Schneider M.P., Etienne M., Unal G., Perré P., Dutheil J.J., Morilland-Lecoq E., Chaillot F. et al., 2021/07. Open forum infectious diseases, 8 (7) pp. ofab316. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A796ED9B414A]
Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.
Courlet P., Guidi M., Alves Saldanha S., Cavassini M., Stoeckle M., Buclin T., Marzolini C., Decosterd L.A., Csajka C., 2021/07. European journal of clinical pharmacology, 77 (7) pp. 979-987. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DCBBE5FFBE88]
 
The association between depressive symptoms and neurocognitive impairment in people with well-treated HIV in Switzerland.
Santos G., Locatelli I., Métral M., Berney A., Nadin I., Calmy A., Tarr P., Gutbrod K., Hauser C., Brugger P. et al., 2021/07. International journal of STD & AIDS, 32 (8) pp. 729-739. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_274D6364F028]
 
Phylogenetic Cluster Analysis Identifies Virological and Behavioral Drivers of Human Immunodeficiency Virus Transmission in Men Who Have Sex With Men.
Bachmann N., Kusejko K., Nguyen H., Chaudron S.E., Kadelka C., Turk T., Böni J., Perreau M., Klimkait T., Yerly S. et al., 2021/06/15. Clinical infectious diseases, 72 (12) pp. 2175-2183. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8580D2E23497]
Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link.
Nguyen H., Thorball C.W., Fellay J., Böni J., Yerly S., Perreau M., Hirsch H.H., Kusejko K., Thurnheer M.C., Battegay M. et al., 2021/06/01. eLife, 10. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CDF338C143A7]
 
Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
Surial B., Mugglin C., Calmy A., Cavassini M., Günthard H.F., Stöckle M., Bernasconi E., Schmid P., Tarr P.E., Furrer H. et al., 2021/06. Annals of internal medicine, 174 (6) pp. 758-767. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_66CF69B98D35]
 
Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIV-1 transmission.
Reichmuth M.L., Chaudron S.E., Bachmann N., Nguyen H., Böni J., Metzner K.J., Perreau M., Klimkait T., Yerly S., Hirsch H.H. et al., 2021/05. HIV medicine, 22 (5) pp. 346-359. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5172F8884D30]
 
The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study.
Glass T.R., Günthard H.F., Calmy A., Bernasconi E., Scherrer A.U., Battegay M., Steffen A., Böni J., Yerly S., Klimkait T. et al., 2021/04/26. Clinical infectious diseases, 72 (8) pp. 1413-1421. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_96376F865BFF]
 
Author Correction: The influence of human genetic variation on Epstein-Barr virus sequence diversity.
Rüeger S., Hammer C., Loetscher A., McLaren P.J., Lawless D., Naret O., Khanna N., Bernasconi E., Cavassini M., Günthard H.F. et al., 2021/04/20..
[DOI][WoS][Pmid][serval:BIB_4F1041DEFB49]
Transplantation de microbiote fécal : de l’évidence aux réalités du terrain [Fecal microbiota transplantation: from the evidence to the realty of the field]
Ballif A., Gerber S., Carrez L., Audry M., Sadeghipour F., Mitouassiwou A., Croxatto A., Opota O., Prod'hom G., Henchoz S. et al., 2021/04/14. Revue medicale suisse, 17 (734) pp. 726-731. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_6F57B9B68184]
 
Random forest machine learning algorithm predicts virologic outcomes among HIV infected adults in Lausanne, Switzerland using electronically monitored combined antiretroviral treatment adherence.
Kamal S., Urata J., Cavassini M., Liu H., Kouyos R., Bugnon O., Wang W., Schneider M.P., 2021/04. AIDS care, 33 (4) pp. 530-536. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C57093B4CF9D]
 
Impact of rosuvastatin on atherosclerosis in people with HIV at moderate cardiovascular risk: a randomised, controlled trial.
Trevillyan J.M., Dart A., Paul E., Cavassini M., Fehr J., Staehelin C., Dewar E.M., Hoy J.F., Calmy A., 2021/03/15. AIDS, 35 (4) pp. 619-624. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6652223060C9]
Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV.
Courlet P., Guidi M., Alves Saldanha S., Stader F., Traytel A., Cavassini M., Stoeckle M., Buclin T., Marzolini C., Decosterd L.A. et al., 2021/03. Clinical pharmacokinetics, 60 (3) pp. 379-390. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CF76FDD25628]
The influence of human genetic variation on Epstein-Barr virus sequence diversity.
Rüeger S., Hammer C., Loetscher A., McLaren P.J., Lawless D., Naret O., Khanna N., Bernasconi E., Cavassini M., Günthard H.F. et al., 2021/02/25. Scientific reports, 11 (1) p. 4586. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0350B2DA3BE2]
Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis.
Hovaguimian F., Günthard H.F., Hauser C., Conen A., Bernasconi E., Calmy A., Cavassini M., Seneghini M., Marzel A., Heinrich H. et al., 2021/02/22. Nature communications, 12 (1) p. 1219. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6F36240CB9E7]
 
Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity.
Livio F., Deutschmann E., Moffa G., Rrustemi F., Stader F., Elzi L., Braun D.L., Calmy A., Hachfeld A., Cavassini M. et al., 2021/02/11. The Journal of antimicrobial chemotherapy, 76 (3) pp. 758-764. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4C33B6D1EDCD]
Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study.
Castillo-Mancilla J.R., Cavassini M., Schneider M.P., Furrer H., Calmy A., Battegay M., Scanferla G., Bernasconi E., Günthard H.F., Glass T.R. et al., 2021/02. Open forum infectious diseases, 8 (2) pp. ofab032. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7D7FF4E6432F]
 
The relationship of smoking and unhealthy alcohol use to the HIV care continuum among people with HIV in an integrated health care system.
Satre D.D., Levine-Hall T., Sterling S.A., Young-Wolff K.C., Lam J.O., Alexeeff S., Hojilla J.C., Williams A., Justice A.C., Sterne J. et al., 2021/02/01. Drug and alcohol dependence, 219 p. 108481. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5C333821E703]
VIH/sida - VIH au temps du Covid-19 : rencontre de deux pandémies [HIV in the time of COVID-19 : the meeting between two pandemics]
Nawej Tshikung O., Buvelot H., Calmy A., Cavassini M., 2021/01/13. Revue medicale suisse, 17 (720-1) pp. 95-101. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BA14B82E0853]
Alcohol consumption and neurocognitive deficits in people with well-treated HIV in Switzerland.
Darling KEA, Locatelli I., Benghalem N., Nadin I., Calmy A., Gutbrod K., Hauser C., Brugger P., Hasse B., Kovari H. et al., 2021. PloS one, 16 (3) pp. e0246579. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F1FCA688B6E3]
2020
Epidemiology of sexually transmitted infections among female sex workers in Switzerland: a local, exploratory, cross-sectional study
Vu F., Cavassini M., D'Acremont V., Greub G., Jaton K., Masserey E., Pongelli S., Bouche L., Ngarambe C., Bize R. et al., 2020/12/14. Swiss medical weekly, 150 pp. w20357. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C47E0DC75726]
 
Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment.
Thorball C.W., Borghesi A., Bachmann N., Von Siebenthal C., Vongrad V., Turk T., Neumann K., Beerenwinkel N., Bogojeska J., Roth V. et al., 2020/12/01. Journal of acquired immune deficiency syndromes, 85 (4) pp. 517-524. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FDF7A2D4587F]
 
Increased CHIP Prevalence Amongst People Living with HIV.
Bick A.G., Popadin K., Thorball C.W., Uddin M.M., Zanni M., Yu B., Cavassini M., Rauch A., Tarr P., Schmid P. et al., 2020/11/07..
[DOI][Pmid][serval:BIB_A38E810FE3BD]
Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART.
Wan C., Bachmann N., Mitov V., Blanquart F., Céspedes S.P., Turk T., Neumann K., Beerenwinkel N., Bogojeska J., Fellay J. et al., 2020/11/02. Nature communications, 11 (1) p. 5542. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EC2E5183286F]
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Sculier D., Wandeler G., Yerly S., Marinosci A., Stoeckle M., Bernasconi E., Braun D.L., Vernazza P., Cavassini M., Buzzi M. et al., 2020/11. PLoS medicine, 17 (11) pp. e1003421. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7D241934CD71]
HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection.
Carlisle L.A., Turk T., Metzner K.J., Mbunkah H.A., Shah C., Böni J., Huber M., Braun D.L., Fehr J., Salazar-Vizcaya L. et al., 2020/10/31. Viruses, 12 (11) pp. E1241. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D73F11FC1FB6]
An Adherence-Enhancing Program Increases Retention in Care in the Swiss HIV Cohort.
Kamal S., Glass T.R., Doco-Lecompte T., Locher S., Bugnon O., Parienti J.J., Cavassini M., Schneider M.P., 2020/09. Open forum infectious diseases, 7 (9) pp. ofaa323. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FAEE71EBE3B0]
 
Authors' reply to A. Winston, A. Cotter, M. Gisslen, P. W. G. Mallon and P. Cinque.
Darling K., Métral M., Du Pasquier R., Cavassini M., Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) Study Group Swiss HIV Cohort Study, 2020/08. HIV medicine, 21 (7) pp. e19-e20. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_57111D226B1B]
Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV.
Courlet P., Decosterd L.A., Alves Saldanha S., Cavassini M., Stader F., Stoeckle M., Buclin T., Marzolini C., Csajka C., Guidi M. et al., 2020/08. Clinical pharmacokinetics, 59 (8) pp. 1037-1048. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B56252981556]
 
Self-reported Neurocognitive Impairment in People Living With Human Immunodeficiency Virus (HIV): Characterizing Clusters of Patients With Similar Changes in Self-reported Neurocognitive Impairment, 2013-2017, in the Swiss HIV Cohort Study.
Kusejko K., Salazar-Vizcaya L., Braun D.L., Tarr P.E., Bernasconi E., Doco-Lecompte T., Cavassini M., Schmid P., Du Pasquier R., Hauser C. et al., 2020/07/27. Clinical infectious diseases, 71 (3) pp. 637-644. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_04E1F806B33A]
 
Blood and Lymph Node Dissemination of Clonal Genome-Intact Human Immunodeficiency Virus 1 DNA Sequences During Suppressive Antiretroviral Therapy.
Kuo H.H., Banga R., Lee G.Q., Gao C., Cavassini M., Corpataux J.M., Blackmer J.E., Zur Wiesch S., Yu X.G., Pantaleo G. et al., 2020/07/23. The Journal of infectious diseases, 222 (4) pp. 655-660. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D6B879F20B5C]
 
Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study.
Surial B., Ledergerber B., Calmy A., Cavassini M., Günthard H.F., Kovari H., Stöckle M., Bernasconi E., Schmid P., Fux C.A. et al., 2020/07/23. The Journal of infectious diseases, 222 (4) pp. 637-645. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4CD4826EDBDF]
 
Real-life management of drug-drug interactions between antiretrovirals and statins.
Courlet P., Livio F., Alves Saldanha S., Scherrer A., Battegay M., Cavassini M., Stoeckle M., Decosterd L.A., Marzolini C., Swiss HIV Cohort Study, 2020/07/01. The Journal of antimicrobial chemotherapy, 75 (7) pp. 1972-1980. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_098C57274A05]
Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies.
Trickey A., May M.T., Gill M.J., Grabar S., Vehreschild J., Wit FWNM, Bonnet F., Cavassini M., Abgrall S., Berenguer J. et al., 2020/06/01. International journal of cancer, 146 (11) pp. 3134-3146. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5DEC7758E430]
Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
Courlet P., Alves Saldanha S., Cavassini M., Marzolini C., Choong E., Csajka C., Günthard H.F., André P., Buclin T., Desfontaine V. et al., 2020/06. Journal of mass spectrometry, 55 (6) pp. e4506. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1D794571C1B2]
 
Aging does not impact drug--drug interaction magnitudes with antiretrovirals.
Stader F., Decosterd L., Stoeckle M., Cavassini M., Battegay M., Saldanha S.A., Marzolini C., Courlet P., and the Swiss HIV Cohort Study, 2020/05/01. AIDS, 34 (6) pp. 949-952. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6666EE49EABD]
How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?
Metral M., Nadin I., Locatelli I., Tarr P.E., Calmy A., Kovari H., Brugger P., Cusini A., Gutbrod K., Schmid P. et al., 2020/05. HIV medicine, 21 (5) pp. 342-348. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E6AE11286152]
Stigmatisation et VIH : tous concernés [Stigma and HIV: relevant for everyone]
Cobos Manuel I., Jackson-Perry D., Courvoisier C., Bluntschli C., Carel S., Muggli E., Waelti Da Costa V., Kampouri E., Cavassini M., Darling KEA, 2020/04/15. Revue medicale suisse, 16 (690) pp. 744-748. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_4B3904FCB2B9]
 
Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate.
Dietrich L.G., Barceló C., Thorball C.W., Ryom L., Burkhalter F., Hasse B., Furrer H., Weisser M., Steffen A., Bernasconi E. et al., 2020/02/14. Clinical infectious diseases, 70 (5) pp. 890-897. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CEFAD592E5CD]
VIH: prévention, traitement et perspectives [Novelties in HIV prevention and treatment in 2019]
Kampouri E., Papadimitriou-Olivgeris M., Calmy A., Ciuffi A., Cavassini M., 2020/01/15. Revue medicale suisse, 16 (676-7) pp. 92-98. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_3AE0F0E2F530]
 
Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients.
Abela I.A., Scherrer A.U., Böni J., Yerly S., Klimkait T., Perreau M., Hirsch H.H., Furrer H., Calmy A., Schmid P. et al., 2020/01/02. Clinical infectious diseases, 70 (2) pp. 297-303. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5CD4824E50AC]
 
Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study: 1980-2018.
Kusejko K., Marzel A., Nguyen H., Chaudron S.E., Bachmann N., Weber R., Bruggmann P., Roth J.A., Bernasconi E., Calmy A. et al., 2020. Antiviral therapy, 25 (1) pp. 43-54. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_957CA76EF559]
Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy.
Barceló C., Guidi M., Thorball C.W., Hammer C., Chaouch A., Scherrer A.U., Hasse B., Cavassini M., Furrer H., Calmy A. et al., 2020/01. Open forum infectious diseases, 7 (1) pp. ofz464. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_7951F9D906D0]
 
Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Courlet P., Stader F., Guidi M., Alves Saldanha S., Stoeckle M., Cavassini M., Battegay M., Buclin T., Decosterd L.A., Marzolini C. et al., 2020/01/01. AIDS, 34 (1) pp. 103-108. Peer-reviewed.
[DOI][Pmid][serval:BIB_B80C7E3E1838]
Repeated Syphilis Episodes in HIV-Infected Men Who Have Sex With Men: A Multicenter Prospective Cohort Study on Risk Factors and the Potential Role of Syphilis Immunity.
Roth J.A., Franzeck F.C., Balakrishna S., Lautenschlager S., Thurnheer M.C., Trellu L.T., Cavassini M., Vernazza P., Bernasconi E., Braun D. et al., 2020/01. Open forum infectious diseases, 7 (1) pp. ofaa019. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A263A2C9DAE8]
The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profile.
Métral M., Darling K., Locatelli I., Nadin I., Santos G., Brugger P., Kovari H., Cusini A., Gutbrod K., Tarr P.E. et al., 2020/01. HIV medicine, 21 (1) pp. 30-42. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_78CE4480FCE1]
2019
Parameter estimates for trends and patterns of excess mortality among persons on antiretroviral therapy in high-income European settings.
Trickey A., van Sighem A., Stover J., Abgrall S., Grabar S., Bonnet F., Berenguer J., Wyen C., Casabona J., d'Arminio Monforte A. et al., 2019/12/15. AIDS, 33 Suppl 3 (Suppl 3) pp. S271-S281. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4D0A49A51A16]
Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV.
Courlet P., Livio F., Guidi M., Cavassini M., Battegay M., Stoeckle M., Buclin T., Alves Saldanha S., Csajka C., Marzolini C. et al., 2019/12. Open forum infectious diseases, 6 (12) pp. ofz531. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_747A12E6A2E6]
 
Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe.
Neesgaard B., Pelchen-Matthews A., Ryom L., Florence E., Peters L., Roen A., Svedhem V., Clarke A., Benfield T., Mitsura V. et al., 2019/11/01. AIDS, 33 (13) pp. 2013-2024. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B83FEB3F3450]
Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort.
Surial B., Cavassini M., Calmy A., Fehr J., Stöckle M., Bernasconi E., Roth B., Fux C.A., Kovari H., Furrer H. et al., 2019/10/10. BMC infectious diseases, 19 (1) p. 834. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_33535700F126]
Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients.
Olearo F., Nguyen H., Bonnet F., Yerly S., Wandeler G., Stoeckle M., Cavassini M., Scherrer A., Costagiola D., Schmid P. et al., 2019/10. Open forum infectious diseases, 6 (10) pp. ofz330. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1A387F35CDFB]
Imaging patterns of Pneumocystis jirovecii pneumonia in HIV-positive and renal transplant patients - a multicentre study.
Christe A., Walti L., Charimo J., Rauch A., Furrer H., Meyer A., Huynh-Do U., Heverhagen J.T., Mueller N.J., Cavassini M. et al., 2019/09/23. Swiss medical weekly, 149 pp. w20130. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_40D99B6F770B]
 
Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.
Courlet P., Guidi M., Glatard A., Alves Saldanha S., Cavassini M., Buclin T., Marzolini C., Eap C.B., Decosterd L.A., Csajka C. et al., 2019/09. British journal of clinical pharmacology, 85 (9) pp. 2022-2032. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F5C6318349C9]
IL-4 polymorphism influences susceptibility to Pneumocystis jirovecii pneumonia in HIV-positive patients.
Wójtowicz A., Bibert S., Taffé P., Bernasconi E., Furrer H., Günthard H.F., Hoffmann M., Osthoff M., Cavassini M., Bochud P.Y. et al., 2019/09. AIDS, 33 (11) pp. 1719-1727. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_8B200C547F87]
 
Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting.
Barcelo C., Aouri M., Courlet P., Guidi M., Braun D.L., Günthard H.F., Piso R.J., Cavassini M., Buclin T., Decosterd L.A. et al., 2019/09/01. The Journal of antimicrobial chemotherapy, 74 (9) pp. 2690-2697. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_525CE7DE74FD]
 
UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV.
Courlet P., Spaggiari D., Desfontaine V., Cavassini M., Alves Saldanha S., Buclin T., Marzolini C., Csajka C., Decosterd L.A., 2019/09/01. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1125 p. 121733. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_00B59FADA800]
 
HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected.
Nguyen H., Thorball C.W., Fellay J., Böni J., Yerly S., Perreau M., Klimkait T., Kusejko K., Bachmann N., Chaudron S.E. et al., 2019/08/15. Journal of acquired immune deficiency syndromes, 81 (5) pp. 508-515. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6E0F5A3E41D4]
 
Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence.
Courlet P., Decosterd L.A., Brown J.A., Alves Saldanha S., Marzolini C., Cavassini M., Stoeckle M., Csajka C., Labhardt N.D., Calmy A. et al., 2019/08/01. The Journal of antimicrobial chemotherapy, 74 (8) pp. 2468-2470. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5082024839D9]
Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017.
Ruffieux Y., Lemsalu L., Aebi-Popp K., Calmy A., Cavassini M., Fux C.A., Günthard H.F., Marzolini C., Scherrer A., Vernazza P. et al., 2019/08. Journal of the International AIDS Society, 22 (8) pp. e25339. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3683258251EB]
Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART.
Bachmann N., von Siebenthal C., Vongrad V., Turk T., Neumann K., Beerenwinkel N., Bogojeska J., Fellay J., Roth V., Kok Y.L. et al., 2019/07/19. Nature communications, 10 (1) p. 3193. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E1256C4C82EF]
Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland.
Santos GMA, Locatelli I., Métral M., Calmy A., Lecompte T.D., Nadin I., Hauser C., Cusini A., Hasse B., Kovari H. et al., 2019/07. Open forum infectious diseases, 6 (7) pp. ofz277. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_80F1939F32B0]
Lymph node migratory dendritic cells modulate HIV-1 transcription through PD-1 engagement.
Banga R., Rebecchini C., Procopio F.A., Noto A., Munoz O., Ioannidou K., Fenwick C., Ohmiti K., Cavassini M., Corpataux J.M. et al., 2019/07. PLoS pathogens, 15 (7) pp. e1007918. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1FF4BBBC8958]
 
A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases.
Kusejko K., Bachmann N., Chaudron S.E., Nguyen H., Braun D.L., Hampel B., Battegay M., Bernasconi E., Calmy A., Cavassini M. et al., 2019/06/19. The Journal of infectious diseases, 220 (2) pp. 244-253. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BB6E66056535]
 
Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection.
Carlisle L.A., Turk T., Kusejko K., Metzner K.J., Leemann C., Schenkel C.D., Bachmann N., Posada S., Beerenwinkel N., Böni J. et al., 2019/06/19. The Journal of infectious diseases, 220 (2) pp. 254-265. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_19B3C834E3FA]
 
Changing Trends in International Versus Domestic HCV Transmission in HIV-Positive Men Who Have Sex With Men: A Perspective for the Direct-Acting Antiviral Scale-Up Era.
Salazar-Vizcaya L., Kouyos R.D., Metzner K.J., Caraballo Cortes K., Böni J., Shah C., Fehr J., Braun D.L., Bernasconi E., Mbunkah H.A. et al., 2019/06/05. The Journal of infectious diseases, 220 (1) pp. 91-99. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DB771CDF18E0]
Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy.
Gras L., May M., Ryder L.P., Trickey A., Helleberg M., Obel N., Thiebaut R., Guest J., Gill J., Crane H. et al., 2019/03/01. Journal of acquired immune deficiency syndromes, 80 (3) pp. 292-300. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1C1B75E2D165]
 
Cost Estimates for Human Immunodeficiency Virus (HIV) Care and Patient Characteristics for Health Resource Use From Linkage of Claims Data With the Swiss HIV Cohort Study.
Leon-Reyes S., Schäfer J., Früh M., Schwenkglenks M., Reich O., Schmidlin K., Staehelin C., Battegay M., Cavassini M., Hasse B. et al., 2019/02/15. Clinical infectious diseases, 68 (5) pp. 827-833. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3E04DC905FA1]
 
Nouveautés dans le dépistage, la prévention et la prise en charge du VIH en 2018 [Diagnosis, prevention and treatment of HIV : what's new in 2018 ?]
D'Incau S., Viala B., Ciuffi A., Cavassini M., Calmy A., 2019/01/09. Revue medicale suisse, 15 (N° 632-633) pp. 107-112. Peer-reviewed.
[Pmid][serval:BIB_0AAA6CA83143]
 
The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study.
Young J., Scherrer A.U., Calmy A., Tarr P.E., Bernasconi E., Cavassini M., Hachfeld A., Vernazza P., Günthard H.F., Bucher H.C. et al., 2019. Antiviral therapy, 24 (5) pp. 343-353. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EE3F2AF63928]
2018
 
Non-targeted HIV testing in the emergency department: not just how but where.
Tan R., Hugli O., Cavassini M., Darling K., 2018/12. Expert review of anti-infective therapy, 16 (12) pp. 893-905. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B54576A3493A]
 
Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma.
Bibert S., Wójtowicz A., Taffé P., Tarr P.E., Bernasconi E., Furrer H., Günthard H.F., Hoffmann M., Kaiser L., Osthoff M. et al., 2018/11/28. AIDS, 32 (18) pp. 2759-2765. Peer-reviewed.
[DOI][Pmid][serval:BIB_8C1E8FCFA728]
 
Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland.
Kusejko K., Marzel A., Hampel B., Bachmann N., Nguyen H., Fehr J., Braun D.L., Battegay M., Bernasconi E., Calmy A. et al., 2018/11. HIV medicine, 19 (10) pp. 688-697. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3BDC797AB74F]
CD32<sup>+</sup> and PD-1<sup>+</sup> Lymph Node CD4 T Cells Support Persistent HIV-1 Transcription in Treated Aviremic Individuals.
Noto A., Procopio F.A., Banga R., Suffiotti M., Corpataux J.M., Cavassini M., Riva A., Fenwick C., Gottardo R., Perreau M. et al., 2018/10/15. Journal of virology, 92 (20). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EFF772664CD3]
Effect of national HIV testing recommendations and local interventions on HIV testing practices in a Swiss university hospital: a retrospective analysis between 2012 and 2015.
Lazzarino T., Martenet S., Mamin R., Du Pasquier R.A., Peters S., Perreau M., Muller O., Hugli O., Cavassini M., Darling KEA, 2018/10/03. BMJ open, 8 (10) pp. e021203. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9B109EF61AEB]
 
Content analysis of antiretroviral adherence enhancing interview reports.
Kamal S., Nulty P., Bugnon O., Cavassini M., Schneider M.P., 2018/09. Patient education and counseling, 101 (9) pp. 1676-1682. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3BCD83D9BF94]
 
Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.
Kouyos R.D., Rusert P., Kadelka C., Huber M., Marzel A., Ebner H., Schanz M., Liechti T., Friedrich N., Braun D.L. et al., 2018/09. Nature, 561 (7723) pp. 406-410. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C1DFE8750F09]
Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study.
Salazar-Vizcaya L., Wandeler G., Fehr J., Braun D., Cavassini M., Stoeckle M., Bernasconi E., Hoffmann M., Rougemont M., Béguelin C. et al., 2018/07. Open forum infectious diseases, 5 (7) pp. ofy154. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DDB0E27A5C73]
Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study.
Kusejko K., Kadelka C., Marzel A., Battegay M., Bernasconi E., Calmy A., Cavassini M., Hoffmann M., Böni J., Yerly S. et al., 2018/07. Virus evolution, 4 (2) pp. vey024. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_65A06455A819]
 
Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men.
Aebi-Popp K., Wandeler G., Salazar-Vizcaya L., Metzner K., Stöckle M., Cavassini M., Hoffmann M., Lüthi A., Suter F., Bernasconi E. et al., 2018/07. HIV medicine, 19 (6) pp. 420-425. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6956BB808421]
Long terms trends in CD4+ cell counts, CD8+ cell counts, and the CD4+ : CD8+ ratio.
Hughes R.A., May M.T., Tilling K., Taylor N., Wittkop L., Reiss P., Gill J., Schommers P., Costagliola D., Guest J.L. et al., 2018/06/19. AIDS, 32 (10) pp. 1361-1367. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B55B1D655205]
Missed opportunities for HIV testing among patients newly presenting for HIV care at a Swiss university hospital: a retrospective analysis.
Lhopitallier L., Moulin E., Hugli O., Cavassini M., Darling KEA, 2018/06/12. BMJ open, 8 (6) pp. e019806. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BCCD5FE237CB]
Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity.
Kadelka C., Liechti T., Ebner H., Schanz M., Rusert P., Friedrich N., Stiegeler E., Braun D.L., Huber M., Scherrer A.U. et al., 2018/06/04. The Journal of experimental medicine, 215 (6) pp. 1589-1608. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6F22C97F0906]
 
Le voyageur face au VIH et le voyageur vivant avec le VIH [Travelers' exposure to HIV and HIV-infected travelers]
Boillat-Blanco N., Cavassini M., Genton B., 2018/05/02. Revue medicale suisse, 14 (605) pp. 918-921. Peer-reviewed.
[Pmid][serval:BIB_B742619C3641]
The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis.
Marzel A., Kusejko K., Weber R., Bruggmann P., Rauch A., Roth J.A., Bernasconi E., Calmy A., Cavassini M., Hoffmann M. et al., 2018/05. Open forum infectious diseases, 5 (5) pp. ofy078. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_284134C473C7]
Single-Cell RNA-Seq Reveals Transcriptional Heterogeneity in Latent and Reactivated HIV-Infected Cells.
Golumbeanu M., Cristinelli S., Rato S., Munoz M., Cavassini M., Beerenwinkel N., Ciuffi A., 2018/04/24. Cell reports, 23 (4) pp. 942-950. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E140228EED10]
 
Are privacy-enhancing technologies for genomic data ready for the clinic? A survey of medical experts of the Swiss HIV Cohort Study.
Raisaro J.L., McLaren P.J., Fellay J., Cavassini M., Klersy C., Hubaux J.P., Swiss HIV Cohort Study, 2018/03. Journal of biomedical informatics, 79 pp. 1-6. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AA11676A72A9]
 
Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study.
Béguelin C., Suter A., Bernasconi E., Fehr J., Kovari H., Bucher H.C., Stoeckle M., Cavassini M., Rougemont M., Schmid P. et al., 2018/03. Liver international, 38 (3) pp. 424-431. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_62355A30C0EF]
 
Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord, Goetghebuer T., 2018/02/01. Clinical infectious diseases, 66 (4) pp. 594-603. Peer-reviewed.
[DOI][Pmid][serval:BIB_498102734DE0]
 
Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?
Mocroft A., Laut K., Reiss P., Gatell J., Ormaasen V., Cavassini M., Hadziosmanovic V., Mansinho K., Pradier C., Vasylyev M. et al., 2018/01/14. AIDS, 32 (2) pp. 205-215. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EECAE37112B1]
 
A prospective multicentre study of healthcare provider preference in rapid HIV testing kits: Determine versus INSTI
Amyai N., Darling K., D'Acremont V., Castro E., Ebert S., Diserens M.M., Perdrix J., Fossati A.H., Bodenmann P., Cavassini M., 2018/01. International journal of STD & AIDS, 29 (1) pp. 51-56. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7E5A2A0B1BFC]
Blood CXCR3 (+) CD4 T Cells Are Enriched in Inducible Replication Competent HIV in Aviremic Antiretroviral Therapy-Treated Individuals.
Banga R., Procopio F.A., Ruggiero A., Noto A., Ohmiti K., Cavassini M., Corpataux J.M., Paxton W.A., Pollakis G., Perreau M., 2018. Frontiers in immunology, 9 p. 144. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_264758601E35]
Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity.
Bertels F., Marzel A., Leventhal G., Mitov V., Fellay J., Günthard H.F., Böni J., Yerly S., Klimkait T., Aubert V. et al., 2018/01/01. Molecular biology and evolution, 35 (1) pp. 27-37. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C087F60FDD69]
 
Epidemiology of sexually transmitted infections among female sex workers in Switzerland : a local exploratory cross-sectional study
Bondolfi C., Vu F., Cavassini M., D'Acremont V., Greub G., Jaton K., Masserey E., Pongelli S., Bouche L., Ngarambe C. et al., 2018., 1st World Congress on Migration, Ethnicity, Race and Health, Edinburgh, 17-19 May 2018 p. 158 dans European Journal of Public Health.
[DOI][WoS][serval:BIB_8266DFADE297]
 
HIV and Aging - Perhaps Not as Dramatic as We Feared?
Engel T., Raffenberg M., Marzolini C., Cavassini M., Kovari H., Hasse B., Tarr P.E., 2018. Gerontology, 64 (5) pp. 446-456. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_92146D8F7DD2]
HIV-infected patients' beliefs about their chronic co-treatments in comparison with their combined antiretroviral therapy.
Kamal S., Bugnon O., Cavassini M., Schneider M.P., 2018/01. HIV medicine, 19 (1) pp. 49-58. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_69D70D1AAC4D]
Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation.
Pettit A.C., Giganti M.J., Ingle S.M., May M.T., Shepherd B.E., Gill M.J., Fätkenheuer G., Abgrall S., Saag M.S., Del Amo J. et al., 2018/01. Journal of the International AIDS Society, 21 (1) pp. NA. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_07BB813C6239]
Molecular characterization of Treponema pallidum subsp. pallidum in Switzerland and France with a new multilocus sequence typing scheme.
Grillová L., Bawa T., Mikalová L., Gayet-Ageron A., Nieselt K., Strouhal M., Sednaoui P., Ferry T., Cavassini M., Lautenschlager S. et al., 2018. PloS one, 13 (7) pp. e0200773. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B0A48A08A0F9]
 
Prescribing issues in the Swiss HIV infected ageing population
Livio F., Rrustemi F., Moffa G., Elzi L., Stader F., Braun D., Calmy A., Hachfeld A., Cavassini M., Tarr P. et al., 2018., 18th International Society of Pharmacovigilance (ISoP) Annual Meeting, Geneva pp. 1252-1253 dans Drug Safety.
[serval:BIB_71ED358A9E04]
Targeted versus non-targeted HIV testing offered via electronic questionnaire in a Swiss emergency department: A randomized controlled study.
Gillet C., Darling KEA, Senn N., Cavassini M., Hugli O., 2018. PloS one, 13 (3) pp. e0190767. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CB2EF1384ACD]
 
Travailleuses du sexe et accès aux soins
Gloor E., Mestre-Augustoni G., Ansemert-Pago A., Vaucher P., Durieux-Paillard S., Bodenmann P., Cavassini M., 2018. pp. 163-172 dans Bodemann Patrick (eds.) Vulnérabilités, équité et santé chap. 2.4, RMS Editions.
[serval:BIB_1779067F07C5]
2017
Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits.
Perrotta G., Bonnier G., Meskaldji D.E., Romascano D., Aydarkhanov R., Daducci A., Simioni S., Cavassini M., Metral M., Lazeyras F. et al., 2017/12. Annals of clinical and translational neurology, 4 (12) pp. 915-920. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_73E580433B39]
 
Mining for pairs: shared clinic visit dates identify steady HIV-positive partnerships.
Marzel A., Shilaih M., Turk T., Campbell N.K., Yang W.L., Böni J., Yerly S., Klimkait T., Aubert V., Furrer H. et al., 2017/10. HIV medicine, 18 (9) pp. 667-676. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8067C283625C]
CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).
Trickey A., May M.T., Schommers P., Tate J., Ingle S.M., Guest J.L., Gill M.J., Zangerle R., Saag M., Reiss P. et al., 2017/09/15. Clinical infectious diseases, 65 (6) pp. 959-966. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F158192EC621]
Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis.
Turk T., Bachmann N., Kadelka C., Böni J., Yerly S., Aubert V., Klimkait T., Battegay M., Bernasconi E., Calmy A. et al., 2017/09/12. eLife, 6 p. 1. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D12FA23D375F]
 
Ethnicity predicts viral rebound after travel to the tropics in HIV-infected travelers to the tropics in the Swiss HIV Cohort Study.
Gebreselassie H.M., Kraus D., Fux C.A., Haubitz S., Scherrer A., Hatz C., Veit O., Stoeckle M., Fehr J., de Lucia S. et al., 2017/09. HIV medicine, 18 (8) pp. 564-572. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_33BB2CCD766D]
Adverse events of raltegravir and dolutegravir.
Elzi L., Erb S., Furrer H., Cavassini M., Calmy A., Vernazza P., Günthard H., Bernasconi E., Battegay M., Swiss HIV Cohort Study Group, 2017/08/24. AIDS, 31 (13) pp. 1853-1858. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_817F925D7859]
 
Impact of screening and antiretroviral therapy on anal cancer incidence in HIV-positive MSM.
Blaser N., Bertisch B., Kouyos R.D., Calmy A., Bucher H.C., Cavassini M., Estill J., Keiser O., Egger M., Swiss HIV Cohort Study, 2017/08/24. AIDS, 31 (13) pp. 1859-1866. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_33A347D9C69C]
 
High prevalence of physical inactivity among patients from the Swiss HIV Cohort Study.
Schäfer J., Young J., Calmy A., Nicca D., Hasse B., Brun Del Re C., Cavassini M., Bernasconi E., Schmidt-Trucksäss A., Bucher H.C. et al., 2017/08. AIDS care, 29 (8) pp. 1056-1061. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A830BDBFE191]
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.
Antiretroviral Therapy Cohort Collaboration, 2017/08. The lancet. HIV, 4 (8) pp. e349-e356. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1A752A9203DA]
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
Sculier D., Gayet-Ageron A., Battegay M., Cavassini M., Fehr J., Hirzel C., Schmid P., Bernasconi E., Calmy A., Swiss HIV Cohort Study, 2017/07/06. BMC infectious diseases, 17 (1) p. 476. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BAB56357C6F7]
 
Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study.
Béguelin C., Friolet N., Moradpour D., Sahli R., Suter-Riniker F., Lüthi A., Cavassini M., Günthard H.F., Battegay M., Bernasconi E. et al., 2017/05/01. Clinical infectious diseases, 64 (9) pp. 1275-1278. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BA76B0AD3D71]
 
Evaluation de la plateforme Neuro-VIH d’un hôpital universitaire par les patients et les médecins traitants [Evaluation of an outpatient multidisciplinary Neuro-HIV clinic by the patients and referring doctors]
Vallotton K., Métral M., Chocron O., Meuli R., Alves D., Du Pasquier R., Cavassini M., 2017/04/12. Revue medicale suisse, 13 (558) pp. 782-786. Peer-reviewed.
[Pmid][serval:BIB_18421788191D]
 
Guidelines : fausse route ou voie dorée ?
Huttner B., Cavassini M., 2017/04/12. Revue medicale suisse, 13 (558) pp. 779-780. Peer-reviewed.
[Pmid][serval:BIB_DCEDBB627C9A]
 
Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
Aouri M., Barcelo C., Guidi M., Rotger M., Cavassini M., Hizrel C., Buclin T., Decosterd L.A., Csajka C., Swiss HIV Cohort Study, 2017/04. Antimicrobial agents and chemotherapy, 61 (1) p. 10. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_551E69A36AD5]
 
Human papillomavirus antibody response following HAART initiation among MSM.
Combes J.D., Clifford G.M., Egger M., Cavassini M., Hirsch H.H., Hauser C., Calmy A., Schmid P., Bernasconi E., Günthard H.F. et al., 2017/02/20. AIDS, 31 (4) pp. 561-569. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_43A9C92AD28E]
 
Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study.
Kovari H., Rauch A., Kouyos R., Rougemont M., Cavassini M., Schmid P., Stöckle M., Bernasconi E., Weber R., Ledergerber B. et al., 2017/02/15. Clinical infectious diseases, 64 (4) pp. 490-497. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B78795F404B2]
Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population.
Gueler A., Moser A., Calmy A., Günthard H.F., Bernasconi E., Furrer H., Fux C.A., Battegay M., Cavassini M., Vernazza P. et al., 2017/01/28. AIDS, 31 (3) pp. 427-436. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CCC3F1E81F81]
Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers.
Chereau F., Madec Y., Sabin C., Obel N., Ruiz-Mateos E., Chrysos G., Fidler S., Lehmann C., Zangerle R., Wittkop L. et al., 2017. PloS one, 12 (4) pp. e0173893. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C649BF89E594]
Patient and doctor perspectives on HIV screening in the emergency department: A prospective cross-sectional study.
De Rossi N., Dattner N., Cavassini M., Peters S., Hugli O., Darling KEA, 2017. PloS one, 12 (7) pp. e0180389. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BA94D80A49E2]
The Presence of Human Immunodeficiency Virus-Associated Neurocognitive Disorders Is Associated With a Lower Adherence to Combined Antiretroviral Treatment.
Kamal S., Locatelli I., Wandeler G., Sehhat A., Bugnon O., Metral M., Du Pasquier R., Gutbrod K., Cavassini M., Schneider M.P. et al., 2017. Open forum infectious diseases, 4 (2) pp. ofx070. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_3B4AA7B205D2]
2016
 
Determinants of HIV-1 broadly neutralizing antibody induction.
Rusert P., Kouyos R.D., Kadelka C., Ebner H., Schanz M., Huber M., Braun D.L., Hozé N., Scherrer A., Magnus C. et al., 2016/11. Nature medicine, 22 (11) pp. 1260-1267. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E6B22356AA9D]
CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART.
Sauter R., Huang R., Ledergerber B., Battegay M., Bernasconi E., Cavassini M., Furrer H., Hoffmann M., Rougemont M., Günthard H.F. et al., 2016/10. Medicine, 95 (42) pp. e5094. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_F2B466D58431]
 
Development of an algorithm for analysing the electronic measurement of medication adherence in routine HIV care.
Rotzinger A., Cavassini M., Bugnon O., Schneider M.P., 2016/10. International journal of clinical pharmacy, 38 (5) pp. 1210-1218. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8A189B13C619]
 
Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I.
Merz L., Zimmermann S., Peters S., Cavassini M., Darling K.E., 2016/10. The oncologist, 21 (10) pp. 1176-1182. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AFAC807D2DC1]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University